Sarepta therapeutics announces expanded us fda approval of elevidys to duchenne muscular dystrophy patients ages 4 and above

Cambridge, mass.--(business wire)--sarepta therapeutics announces the expanded u.s. fda approval of elevidys to duchenne muscular dystrophy patients ages 4 and above.

SRPT Ratings Summary

SRPT Quant Ranking